Steroid profiling in the differential diagnosis of Cushing’s syndrome and diagnosis of MACS
DOI:
https://doi.org/10.2478/AMB-2024-0012Keywords:
Cushing’s syndrome, adrenal incidentalomas, steroid profiling, mild autonomous cortisol secretionAbstract
Background: Cushing’s syndrome (CS) is the consequence of the exposure of tissues to extremely high levels of glucocorticoids. Early diagnosis and treatment are the mainstay of optimizing patient outcomes and improving their quality of life. In the recent years steroid profiling by LC-MS sheds more light on the diagnosis of CS. Materials and methods: This was a retrospective cross-sectional study. Objective: To investigate serum steroid precursor differences between different etiological forms of CS and to suggest a
steroid panel for the diagnosis of MACS in patients with adrenal incidentalomas. Results: Our studied patients with CD had significantly lower levels of 11-deoxycorticosterone (p = 0.047) and 17 OH progesterone (p = 0.024) compared to those with adrenal forms of CS. In out cohort of patients with adrenal incidentalomas, those with MACS had significantly lower levels of androgens (DHEA, p = 0.001) and cortisone (p = 0.015) and higher levels of 11-deoxycortisol (p = 0.039) compared to the patients with non-secreting adenomas (NSA). Conclusion: Introducing LC-MS based steroid profiling would be very helpful in the diagnostic process of patients with CS.
References
Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing’s syndrome. Vol. 35, Best Practice and Research: Clinical Endocrinology and Metabolism. Bailliere Tindall Ltd; 2021.
Ferriere A, Tabarin A. Cushing’s syndrome: Treatment and new therapeutic approaches. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101381.
Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Vol. 9, The Lancet Diabetes and Endocrinology. Elsevier
Ltd; 2021, 847-75.
Barbot M, Zilio M, Scaroni C. Cushing’s syndrome: Overview of clinical presentation, diagnostic tools and complications. Vol. 34, Best Practice and Research: Clinical Endocrinology
and Metabolism. Bailliere Tindall Ltd; 2020.
Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing’s syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526-40.
Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021; 9(12):847-75.
Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the
European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023; 189(1):G1-42. 8. Delivanis DA, Athimulam S, Bancos I. Modern Management of Mild Autonomous Cortisol Secretion. Clin Pharmacol Ther.
; 106(6):1209-21.
Taylor DR, Ghataore L, Couchman L, et al. A 13-steroid serum panel based on LC-MS/MS: Use in detection of adrenocortical carcinoma. Clin Chem. 2017; 63(12):1836-46.
Kerkhofs TMA, Kerstens MN, Kema IP, et al. Diagnostic Value of Urinary Steroid Profiling in the Evaluation of Adrenal Tumors. Horm Cancer. 2015; 6(4):168-75.
Hines JM, Bancos I, Bancos C, et al. High-resolution, accurate-mass (HRAM) mass spectrometry urine steroid profiling in the diagnosis of adrenal disorders. Clin Chem. 2017;
(12):1824-35.
Eisenhofer G, Masjkur J, Peitzsch M, et al. Plasma steroid metabolome profiling for diagnosis and subtyping patients with cushing syndrome. Clin Chem. 2018; 64(3):586-96.
Park SS, Kim JH. Recent Updates on the Management of Adrenal Incidentalomas. Vol. 38, Endocrinology and Metabolism. Korean Endocrine Society; 2023, 373-80.
Yaneva M, Mosnier-Pudar H, Dugué MA, et al. Midnight salivary cortisol for the initial diagnosis of Cushing’s syndrome of various causes. J Clin Endocrinol Metab. 2004; 89(7):3345-51.
Yamaji T, Ishibashi M, Sekihara H, et al. Serum dehydroepiandrosterone sulfate in cushing’s syndrome. J Clin Endocrinol Metab. 1984; 59(6):1164-8.
Kikuchi E, Yanaihara H, Nakashima J, et al. Urinary steroid profile in adrenocortical tumors. Biomed Pharmacother. 2000; 54(SUPPL. 1):194s-197s.
Lin CL, Wu TJ, Machacek DA, et al. Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab. 1997; 82(1):151-5.
Ueshiba H. A method for the quantitative analysis of steroid hormones by HPLC/RIA. Nippon Naibunpi Gakkai zasshi.1987; 63(6):809-22.
Gao C, Ding L, Zhang X, et al. Distinct serum steroid profiles between adrenal Cushing syndrome and Cushing disease. Front Endocrinol (Lausanne). 2023; 14(May):-8.
Sema C, Ozlem S, Alev S, et al. The importance of DHEA-s levels in cushing’s syndrome; is there a cut-off value in the differential diagnosis? Horm Metab Res. 54(4):232-:232-7.
Athimulam S, Grebe S, Bancos I. Steroid profiling in the diagnosis of mild and overt Cushing’s syndrome. Vol. 35, Best Practice and Research: Clinical Endocrinology and Metabolism. Bailliere Tindall Ltd; 2021.
Di Dalmazi G, Fanelli F, Mezzullo M, et al. Steroid profiling by LC-MS/MS in nonsecreting and subclinical cortisol-secreting adrenocortical adenomas. J Clin Endocrinol Metab. 2015;
(9):3529-38.
Berke K, Constantinescu G, Masjkur J, et al. Plasma Steroid Profiling in Patients with Adrenal Incidentaloma. J Clin Endocrinol Metab. 2022; 107(3):E1181-92.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 A. Nankova, T. Kamenova, V. Vasilev, A. Elenkova, D. Svinarov, G. Kirilov, S. Zaharieva (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
